Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Femasys Inc (FEMY)
Femasys Inc (FEMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,743
  • Shares Outstanding, K 21,650
  • Annual Sales, $ 1,210 K
  • Annual Income, $ -11,390 K
  • 60-Month Beta -3.70
  • Price/Sales 16.87
  • Price/Cash Flow N/A
  • Price/Book 2.24
Trade FEMY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +20.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7340 +93.46%
on 01/31/24
1.6195 -12.32%
on 02/23/24
+0.6250 (+78.62%)
since 01/23/24
3-Month
0.7340 +93.46%
on 01/31/24
1.6195 -12.32%
on 02/23/24
+0.5062 (+55.40%)
since 11/22/23
52-Week
0.2479 +472.81%
on 09/18/23
4.7500 -70.11%
on 10/02/23
+0.1700 (+13.60%)
since 02/23/23

Most Recent Stories

More News
5 of the Most Active Penny Stocks Worth Your Precious Time

These are five of the Most Active Penny Stocks in October that investors may find worthy of investment for 2024 and beyond

CHPT : 1.9000 (-1.04%)
SABR : 2.73 (-3.87%)
FEMY : 1.4200 (-2.74%)
NKLA : 0.7643 (+8.91%)
GRAB : 3.16 (unch)
Stock Index Futures Plunge as Investors Weigh Interest Rate Outlook

December S&P 500 futures (ESZ23) are down -0.40%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.53% this morning as market participants continued to price in an extended period of elevated...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
AMZN : 174.99 (+0.23%)
NVDA : 788.17 (+0.36%)
SEE : 36.58 (+3.16%)
HPQ : 29.27 (+1.11%)
COST : 737.93 (+0.48%)
CTAS : 633.10 (+0.96%)
FERG : 207.56 (+0.15%)
ASC.LN : 367.300 (-0.22%)
DKNG : 41.28 (+1.08%)
FEMY : 1.4200 (-2.74%)
Femasys Inc. (FEMY) Reports Q3 Loss, Lags Revenue Estimates

Femasys Inc. (FEMY) delivered earnings and revenue surprises of -8.70% and 13.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

FEMY : 1.4200 (-2.74%)
ICVX : 15.31 (-0.91%)
Voyager Therapeutics (VYGR) Beats Q3 Earnings and Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 336.84% and 93.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

VYGR : 8.18 (+6.10%)
FEMY : 1.4200 (-2.74%)
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update

Continued focus and progress with FemaSeed® and FemBloc® biomedical product candidates in developmentFemCerv® and FemCath™ commercial availability expected...

FEMY : 1.4200 (-2.74%)
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of -16.46% and 12.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ITCI : 70.16 (-2.46%)
FEMY : 1.4200 (-2.74%)
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 32.29% and 3.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CHRS : 2.58 (+4.45%)
FEMY : 1.4200 (-2.74%)
Femasys To Host Key Opinion Leader Event on FemBloc, a First-of-its-Kind Medical Solution for Permanent Birth Control and an Important Option for Women Post Overturn of Roe v. Wade

Webinar to be held Thursday, July 28th @ 10:30am EDT...

FEMY : 1.4200 (-2.74%)
Femasys to Participate in the Women’s Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ET

ATLANTA, July 11, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite...

FEMY : 1.4200 (-2.74%)
2 Contraceptive Stocks That Could Benefit Following Roe v. Wade Reversal

Recent events, particularly the reversal of the long-standing Roe v. Wade decision that guaranteed women’s right to have an abortion, have put women’s health matters squarely in the spotlight. It also...

EVFM : 0.0250 (-6.72%)
FEMY : 1.4200 (-2.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Femasys Inc.is a biomedical company focused on transforming women's healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The company's lead product candidates offer FemBloc and FemaSeed. Femasys Inc. is based in ATLANTA.

See More

Key Turning Points

3rd Resistance Point 1.8592
2nd Resistance Point 1.7393
1st Resistance Point 1.5797
Last Price 1.4200
1st Support Level 1.3002
2nd Support Level 1.1803
3rd Support Level 1.0207

See More

52-Week High 4.7500
Fibonacci 61.8% 3.0302
Fibonacci 50% 2.4990
Fibonacci 38.2% 1.9677
Last Price 1.4200
52-Week Low 0.2479

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar